Betamethasone topical Alternatives Compared
| Betamethasone topical | Dupixent (dupilumab) | Rinvoq (upadacitinib) |
|
|---|
| Betamethasone topical | Dupixent (dupilumab) | Rinvoq (upadacitinib) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Betamethasone topical is the name for multiple betamethasone preparations that vary in potency from medium to super-high depending on the concentration of betamethasone, the vehicle, the salt used... View more |
Prescription only
Dupixent injection is usually given every 1 to 4 weeks to treat asthma, eczema, chronic rhinosinusitis, COPD, eosinophilic esophagitis, or prurigo nodularis. Injection site reactions and eye problems... View more |
Prescription only
Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Rheumatoid... View more |
Related suggestions Atopic Dermatitis
Popular comparisons
|
|||||||||||||||||||||||
| More about Betamethasone topical | More about Dupixent (dupilumab) | More about Rinvoq (upadacitinib) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Betamethasone topical has an average rating of 8.3 out of 10 from a total of 56 ratings on Drugs.com. 79% of reviewers reported a positive effect, while 9% reported a negative effect. |
Dupixent has an average rating of 7.2 out of 10 from a total of 500 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 20% reported a negative effect. |
Rinvoq has an average rating of 7.0 out of 10 from a total of 224 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Betamethasone topical side effects |
View all Dupixent side effects |
View all Rinvoq side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Betamethasone topical prices |
View all Dupixent prices |
View all Rinvoq prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Beta-Val, Betnovate, Diprolene, Diprolene AF, Luxiq, Sernivo |
N/A |
Other upadacitinib brands include: Rinvoq LQ | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
6.5 hours |
N/A |
14 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 48 drugs are known to interact with Betamethasone topical:
|
A total of 92 drugs are known to interact with Dupixent:
|
A total of 596 drugs are known to interact with Rinvoq:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 02, 1967 |
March 28, 2017 |
August 16, 2019 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.